hydroxychloroquine has been researched along with Scotoma in 36 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Scotoma: A localized defect in the visual field bordered by an area of normal vision. This occurs with a variety of EYE DISEASES (e.g., RETINAL DISEASES and GLAUCOMA); OPTIC NERVE DISEASES, and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 7.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| "To assess the sensitivity and specificity of microperimetry as a screening test to detecting hydroxychloroquine retinopathy." | 3.91 | MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. ( Iftikhar, M; Kaur, R; Kherani, S; Nefalar, A; Petri, M; Rashid, I; Scholl, HPN; Schönbach, E; Shah, SM; Usmani, B, 2019) |
| "A 61-year-old woman with rheumatoid arthritis treated with 400 mg/kg hydroxychloroquine daily for 6 years (daily dose, 5." | 3.88 | Case Report: Hydroxychloroquine Retinopathy. ( Chan, EW; Eldeeb, M; Omar, A, 2018) |
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 3.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| " Differential diagnoses include Leber's congenital amaurosis, central gyrate atrophy, central areolar choroidal sclerosis, progressive cone-rod dystrophy, syphilitic retinopathy, retinal toxicity from phenothiazine use, and chloroquine/hydroxychloroquine retinopathy." | 3.70 | Retinitis pigmentosa inversa. ( Anderson, SF; Ferrucci, S; Townsend, JC, 1998) |
| "Nineteen patients identified scotomata on red Amsler grid." | 2.71 | Utility of red amsler grid screening in a rheumatology clinic. ( Blomquist, PH; Pluenneke, AC, 2004) |
| "Red fields often showed more prominent scotomas in early retinopathy but sometimes showed irregular losses that were hard to evaluate." | 1.39 | Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. ( Chien, FY; Johnson, MW; Marmor, MF, 2013) |
| "In addition, she had a central scotoma (RE > LE) on automated visual field analysis (Humphrey central 30 degrees )." | 1.36 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. ( Leroy, BP; Salu, P; Uvijls, A; van den Brande, P, 2010) |
| " Its use has been associated with ocular side effects; the most concerning is toxic maculopathy." | 1.35 | Retinal toxicity secondary to Plaquenil therapy. ( Hanna, B; Holdeman, NR; Schiffman, JS; Tang, RA, 2008) |
| "Additionally, the average area of each scotoma detected by all three methods expanded from 34." | 1.33 | Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. ( Almony, A; Garg, S; Kitridou, R; Mamet, R; Peters, RK; Sadun, AA; Shibuya, B; Tsong, J, 2005) |
| " Risk factors for the development of toxicity are daily dosage related to body weight, total drug dosage and the specific drug used." | 1.31 | (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines. ( Herman, K; Leys, A; Spileers, W, 2002) |
| "All cases arose because of failure by physicians to avoid dosing above published safe levels." | 1.31 | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. ( Browning, DJ, 2002) |
| "Four cases of irreversible bilateral scotomas were detected in 8 eyes of 4 patients with normal static and kinetic fields in 7 of the 8 eyes." | 1.27 | The sensitivity of Amsler grid testing in early chloroquine retinopathy. ( Easterbrook, M, 1985) |
| "Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results." | 1.25 | Ocular manifestations of juvenile rheumatoid arthritis. ( Bellows, AR; Bienfang, DC; Chylack, LT; Stillman, JS, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (19.44) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 9 (25.00) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chew, AL | 1 |
| Sampson, DM | 1 |
| Chelva, E | 1 |
| Khan, JC | 1 |
| Chen, FK | 1 |
| Eldeeb, M | 1 |
| Chan, EW | 1 |
| Omar, A | 1 |
| Iftikhar, M | 1 |
| Kaur, R | 1 |
| Nefalar, A | 1 |
| Usmani, B | 1 |
| Kherani, S | 1 |
| Rashid, I | 1 |
| Schönbach, E | 1 |
| Petri, M | 1 |
| Scholl, HPN | 1 |
| Shah, SM | 1 |
| Grassi, MA | 1 |
| Maker, MP | 1 |
| Marmor, MF | 4 |
| Pham, BH | 1 |
| Modi, YS | 1 |
| Singh, RP | 1 |
| Proano, C | 1 |
| Kimball, GP | 1 |
| Messiant, V | 1 |
| Defoort-Dhellemmes, S | 1 |
| Smirnov, V | 1 |
| Chien, FY | 1 |
| Johnson, MW | 1 |
| Freund, PR | 1 |
| MacDonald, IM | 1 |
| Easterbrook, M | 6 |
| Opremcak, EM | 1 |
| Buscombe, CP | 1 |
| Lin, S | 1 |
| Wilson-Holt, NJ | 1 |
| Melles, RB | 1 |
| Navajas, EV | 1 |
| Krema, H | 1 |
| Hammoudi, DS | 1 |
| Lipton, JH | 1 |
| Simpson, ER | 1 |
| Boyd, S | 1 |
| Salu, P | 1 |
| Uvijls, A | 1 |
| van den Brande, P | 1 |
| Leroy, BP | 1 |
| Herman, K | 1 |
| Leys, A | 1 |
| Spileers, W | 1 |
| Penrose, PJ | 1 |
| Tzekov, RT | 1 |
| Sutter, EE | 1 |
| Fu, AD | 1 |
| Allen, AW | 1 |
| Fung, WE | 1 |
| Oxford, KW | 1 |
| Pluenneke, AC | 1 |
| Blomquist, PH | 1 |
| Teoh, SC | 1 |
| Lim, J | 1 |
| Koh, A | 1 |
| Lim, T | 1 |
| Fu, E | 1 |
| Lee, AG | 1 |
| Almony, A | 1 |
| Garg, S | 1 |
| Peters, RK | 1 |
| Mamet, R | 1 |
| Tsong, J | 1 |
| Shibuya, B | 1 |
| Kitridou, R | 1 |
| Sadun, AA | 1 |
| Zajdenweber, ME | 1 |
| Muccioli, C | 1 |
| Moraes, RT | 1 |
| Logan, P | 1 |
| Fernandes, BF | 1 |
| Burnier, MN | 1 |
| Hanna, B | 1 |
| Holdeman, NR | 1 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Rynes, RI | 1 |
| Ferrucci, S | 1 |
| Anderson, SF | 1 |
| Townsend, JC | 1 |
| Browning, DJ | 1 |
| Brinkley, JR | 1 |
| Dubois, EL | 1 |
| Ryan, SJ | 1 |
| Chylack, LT | 1 |
| Bienfang, DC | 1 |
| Bellows, AR | 1 |
| Stillman, JS | 1 |
| François, J | 1 |
| de Rouck, A | 1 |
| Cambie, E | 1 |
| de Laey, JJ | 1 |
| Nylander, U | 1 |
| Bertrand, JJ | 1 |
| Debeyre, N | 1 |
| Kahn, MF | 1 |
| Ryckewaert, A | 1 |
1 trial available for hydroxychloroquine and Scotoma
| Article | Year |
|---|---|
Utility of red amsler grid screening in a rheumatology clinic.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; False Positive Reactions; Female; Humans; Hydroxychloro | 2004 |
35 other studies available for hydroxychloroquine and Scotoma
| Article | Year |
|---|---|
Perifoveal interdigitation zone loss in hydroxychloroquine toxicity leads to subclinical bull's eye lesion appearance on near-infrared reflectance imaging.
Topics: Antirheumatic Agents; Electroretinography; Fluorescein Angiography; Fovea Centralis; Humans; Hydroxy | 2018 |
Case Report: Hydroxychloroquine Retinopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Fluorescein Angiography; H | 2018 |
MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study.
Topics: Adult; Aged; Antirheumatic Agents; Enzyme Inhibitors; Female; Fluorescein Angiography; Humans; Hydro | 2019 |
Night Blindness, Ring Scotoma, and a Nonrecordable Electroretinogram in an Elderly Woman.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Night Blindness | 2019 |
SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity.
Topics: Antirheumatic Agents; Disease Progression; Enzyme Inhibitors; Female; Fluorescein Angiography; Fovea | 2019 |
Bull's-Eye Maculopathy Associated with Hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Macular Degeneratio | 2019 |
Hydroxychloroquine Retinal Toxicity.
Topics: Antirheumatic Agents; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2019 |
[Atypical hydroxychloroquine maculopathy in an Asian woman with lupus].
Topics: Adult; Asian People; Female; Genetic Predisposition to Disease; Humans; Hydroxychloroquine; Laos; Lu | 2019 |
Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxych | 2013 |
Re: Monitoring patients on antimalarials: where are we now?
Topics: Antimalarials; Color Vision Defects; Drug Monitoring; Female; Humans; Hydroxychloroquine; Retina; Sc | 2013 |
Re: monitoring patients on antimalarials: where are we now? Author reply.
Topics: Antimalarials; Color Vision Defects; Drug Monitoring; Female; Humans; Hydroxychloroquine; Retina; Sc | 2013 |
Plaquenil toxicity.
Topics: Aged; Antirheumatic Agents; Diagnosis, Differential; Electroretinography; Female; Humans; Hydroxychl | 2013 |
Blurred vision: targeting a diagnosis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Female; Hum | 2013 |
Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychl | 2014 |
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Topics: Adult; Aged; Antimalarials; Chronic Disease; Color Vision Defects; Electroretinography; Female; Graf | 2015 |
Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.
Topics: Antirheumatic Agents; Contrast Sensitivity; Disease Progression; Electroretinography; Female; Fluore | 2010 |
Monitoring patients on antimalarials: where are we now?
Topics: Academies and Institutes; Antimalarials; Arthritis; Body Constitution; Color Vision Defects; Drug Mo | 2012 |
(Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Scotoma | 2002 |
Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Male; Mi | 2003 |
Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity.
Topics: Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Middle Aged; Retina; | 2006 |
Hydroxychloroquine screening.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Screening | 2005 |
Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy.
Topics: Adult; Aged; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Di | 2005 |
Localized retinal ischemia as an ocular manifestation of primary antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Fluorescein Angiography; Humans; Hydroxychloroquine; Ischemia; Mal | 2007 |
Retinal toxicity secondary to Plaquenil therapy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Follow-Up Studie | 2008 |
Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Evaluation; Humans; Hydroxychloroquine; Middle Aged; Ophtha | 1983 |
The ocular safety of hydroxychloroquine.
Topics: Female; Humans; Hydroxychloroquine; Incidence; Male; Prognosis; Prospective Studies; Retinal Disease | 1993 |
Retinitis pigmentosa inversa.
Topics: Adult; Atrophy; Blindness; Chloroquine; Diagnosis, Differential; Follow-Up Studies; Humans; Hydroxyc | 1998 |
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse | 2002 |
Long-term course of chloroquine retinopathy after cessation of medication.
Topics: Adult; Aged; Chloroquine; Color Perception Tests; Female; Fluorescein Angiography; Follow-Up Studies | 1979 |
Ocular manifestations of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Juvenile; Atropine; Cataract; Ch | 1975 |
Long-term course of antimalarial maculopathy after cessation of treatment.
Topics: Chloroquine; Follow-Up Studies; Humans; Hydroxychloroquine; Longitudinal Studies; Macula Lutea; Mala | 1992 |
The sensitivity of Amsler grid testing in early chloroquine retinopathy.
Topics: Adult; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Tests | 1985 |
[Chloroquine retinopathy].
Topics: Adult; Aged; Chloroquine; Color Vision Defects; Dark Adaptation; Electrooculography; Electroretinogr | 1972 |
Ocular damage in chloroquine therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Color Perception Tests; Color Vision Defects; Corn | 1967 |
[Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
Topics: Antimalarials; Chloroquine; Corneal Opacity; Drug Tolerance; Electroretinography; Eye Diseases; Hydr | 1968 |